Ones To Watch News
Refine Search
Pharmaceutical
Marking its second deal this month alone, Novo Nordisk has entered into a multi-year collaboration with Massachusetts, USA-based Photys Therapeutics to develop novel proximity-based therapeutics for a cardiometabolic disease target. 18 December 2024
Biotechnology
Cara Therapeutics and Tvardi Therapeutics have announced a definitive agreement to merge, creating a new entity under the Tvardi name. 18 December 2024
Pharmaceutical
SiteOne Therapeutics has announced the completion of a $100 million series C financing, led by Novo Holdings, with participation from OrbiMed, Wellington Management, Mission BioCapital, and others. 18 December 2024
Biotechnology
Flagship Pioneering-founded genome engineering biotech Tessera Therapeutics today announced an investment of up to $50 million from the Bill & Melinda Gates Foundation to develop curative, globally accessible in vivo genetic therapies for sickle cell disease. 18 December 2024
Biotechnology
San Francisco-based Indapta Therapeutics, a privately held start-up developing next-generation cell therapies, has raised $22.5 million in a new financing round. The firm raised over $50 million in series A funding in 2022. 18 December 2024
Biotechnology
French CNS specialist Theranexus saw its shares leap more than 34% to 0.65 euros as it revealed a license and supply agreement with Exeltis to commercialize TX01, its novel formulation of a compound already approved in the indication for the treatment of rare neurological diseases. 18 December 2024
Biotechnology
Shares in US biopharma Viridian Therapeutics shot up by 21% on Monday. 17 December 2024
Biotechnology
US antivirals giant Gilead Sciences today revealed it has entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets with Californian biotech Terray Therapeutics. 17 December 2024
Pharmaceutical
Swedish biotech company Inify Laboratories has raised approximately 135 million kroner ($12.3 million) through a private placement, supporting a planned expansion into the UK. 16 December 2024
Biotechnology
Dewpoint Therapeutics and ConcertAI have announced the first phase of their translational oncology partnership, aligned around the former company's latest drug candidate, DPTX3186. 16 December 2024
Biotechnology
Bicycle Therapeutics, a UK-headquartered pharma company developing a new class of therapeutics based on its proprietary bicyclic peptide technology, closed a third lower on Friday. 16 December 2024
Biotechnology
In a filing with the US financial regulator, German mRNA specialist BioNTech has noted the lifting of a partial clinical hold on its PRESERVE-003 trial. 16 December 2024
Biotechnology
VectorY Therapeutics, a Netherlands-based biotech focused on neurodegenerative diseases, has appointed Jim Scibetta as chief executive officer. 16 December 2024
Biotechnology
Sino-American biotech BeiGene has announced it has entered into a global licensing agreement with China’s CSPC Zhongqi Pharmaceutical Technology for SYH2039, a novel methionine adenosyltransferase 2A (MAT2A)-inhibitor being explored for solid tumors. 13 December 2024
Pharmaceutical
US biotech Corcept Therapeutics has reported positive results from the Phase IV CATALYST study of Korlym (mifepristone) in people with hypercortisolism and difficult-to-control type 2 diabetes. 13 December 2024
Pharmaceutical
UK-based Tenpoint Therapeutics and Seattle’s Visus Therapeutics have announced the completion of their merger to create an entirely new chapter in ophthalmic therapeutic medicines aimed at rejuvenating the aging eye. 12 December 2024
Biotechnology
USA-based Elevation Oncology, an innovative oncology company focused on the discovery and development of selective cancer therapies, has entered into a licensing agreement with Synaffix, part of Swiss out-sourcing major Lonza. 12 December 2024
Pharmaceutical
US clinical-stage drug developer Keros Therapeutics’ shares plummeted more than 73% to $18.20 in pre-market activity on revealing a setback for a lead investigational candidate. 12 December 2024
Pharmaceutical
UK-based Essential Pharma has announced the completion of a 900 million euros ($945 million) financing. 12 December 2024
Biotechnology
California-based Angitia Biopharmaceuticals, a biotech focused on the discovery and development of innovative therapeutics for serious musculoskeletal diseases, has announced the closing of a $120 million Series C financing round. 12 December 2024
Biotechnology
Shares of US clinical-stage biotech Biohaven rose 9.6% to $21.74 yesterday, after it announced an agreement with Oberland Capital Management for an investment of up to $600 million in the company, with the first tranche of $250 million of gross proceeds to be funded at closing on or before April 30, 2025. 29 April 2025
Biotechnology
Early-stage biotech Nova Anchora has secured a new investment to move its lead therapy for epidermolysis bullosa (EB) closer to clinical trials. 29 April 2025
Biotechnology
USA-based Medicus Pharma has agreed to acquire UK firm Antev for around $75 milln in a share exchange deal. 28 April 2025
Pharmaceutical
After reported discussions since February, German pharma and sciences company Merck KGaA has confirmed its intension to acquire the US drug developer SpringWorks Therapeutics. 28 April 2025
Biotechnology
In one of the largest all-private licensing deals so far this year, worth around 500 million euros ($569 million), Netherlands-based Prilenia Therapeutics and Spain’s Ferrer today announced a co-development and commercialization agreement for Prilenia’s oral sigma-1 receptor agonist, pridopidine, for Europe and other select international markets. 28 April 2025
Biotechnology
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) late Friday announced it has granted a conditional marketing authorization for the Aucatzyl (obecabtagene autoleucel), a chimeric antigen receptor (CAR) T-cell therapy, to treat adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). 28 April 2025
Pharmaceutical
Opening the door to wider treatment access and faster adoption of oral therapies for obstructive sleep apnea (OSA) and other sleep-related breathing diseases, Cambridge, USA-based Apnimed has acquired the intellectual property and exclusive global rights to develop and commercialize sulthiame, a differentiated carbonic anhydrase inhibitor, from Germany’s Desitin Arzneimittel. 28 April 2025
Pharmaceutical
Precision oncology company Guardant Health has announced a strategic collaboration with Pfizer to support the development and commercialization of the US pharma giant’s cancer portfolio using the Guardant Infinity smart liquid biopsy platform. 25 April 2025
Biotechnology
Chinese biotech LTZ Therapeutics has closed an oversubscribed series A+ financing round, raising $40 million to support its push into early-stage clinical development. 25 April 2025
Biotechnology
Swiss-American biotech Granite Bio has exited stealth mode with $100 million in funding and plans to advance two experimental antibodies aimed at a range of autoimmune conditions. 25 April 2025
Biotechnology
Dutch biotech Avidicure has launched with $50 million in seed financing to support development of a novel class of multifunctional antibody therapies for cancer. 24 April 2025
Pharmaceutical
Zurich-based biotech MetrioPharm has appointed Stephan Rietiker as chair of its board of directors, following a unanimous vote by the newly formed board. 24 April 2025
Biotechnology
US biotech Grove Biopharma has secured $30 million in a series A round to move its lead program targeting advanced prostate cancer into clinical trials and expand development of its synthetic biology platform, known as Bionic Biologics. 24 April 2025
Biotechnology
Autoimmune diseases specialist Immunovant has announced changes to its leadership team and the expanded development of its drug IMVT-1402 into two new indications, Sjögren’s disease (SjD) and cutaneous lupus erythematosus (CLE). 23 April 2025
Biotechnology
Cambridge, USA-based biotech Repertoire Immune Medicines today announced a collaboration and license agreement with Genentech, a subsidiary of Swiss pharma giant Roche, to discover and develop innovative T cell-targeted immune medicines to treat an autoimmune disease. 23 April 2025
Pharmaceutical
German family-owned pharma major Boehringer Ingelheim and Dutch precision oncology company Tessellate Bio have entered into a research collaboration and global license agreement. 23 April 2025
Biotechnology
Xlife Sciences says that Veraxa Biotech is to list as a public company on the Nasdaq Global Market through a strategic merger with the special purpose acquisition company Voyager Acquisition Corp. 23 April 2025
Biotechnology
San Diego-based iBio, an AI-driven innovator of precision antibody therapies, has announced a licensing agreement with privately-held US biotech AstralBio. 22 April 2025
Biotechnology
US clinical-stage biotech Halda Therapeutics today announced that Dr Eyal Attar has joined the company as chief medical officer (CMO). Dr Attar brings to Halda over 25 years of biotechnology R&D and clinical trial experience in the advancement of novel therapeutics. 22 April 2025
Biotechnology
Japan’s Ono Pharmaceutical and privately-held US firm Jorna Therapeutics are ready to go in a research collaboration agreement that they signed in December of last year. 22 April 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze